Reevaluation of PSA Monitoring in Advanced Prostate Cancer

Recent research suggests that relying solely on prostate-specific antigen (PSA) levels may be inadequate for monitoring tumor progression in patients with advanced prostate cancer. A collaborative study by Weill Cornell Medicine and Duke University highlights the potential need for periodic imaging, even when PSA levels remain stable.

Published in the Journal of Clinical Oncology, the study examined data from over 2,500 men participating in phase 3 clinical trials (ARCHES and PROSPER) involving the drug enzalutamide. Enzalutamide targets the androgen receptor, which plays a role in cancer cell growth through hormone signaling. These trials assessed tumor progression through imaging modalities such as X-rays, CT scans, and bone scans, alongside monitoring PSA levels.

Remarkably, the findings revealed that up to 25% of patients experienced radiographic tumor progression without any corresponding increase in PSA levels. "PSA has long been one of the most important tools for tracking prostate cancer, but these results show that waiting for PSA levels to rise may miss cancer growth or spread in some patients receiving modern targeted therapies," said Dr. Cora N. Sternberg, senior author and professor at Weill Cornell Medicine. Dr. Andrew Armstrong of Duke University is the study's first author.

In the ARCHES study, even patients responding to hormone therapy showed imaging evidence of cancer progression despite stable PSA levels. Similar observations were made in the PROSPER trial, involving patients with non-metastatic castration-resistant prostate cancer. In both trials, imaging-detected tumor progression correlated with poorer overall survival, regardless of PSA level changes.

An intriguing aspect of this research is the possible disconnect between PSA production and cancer progression. As tumors adapt, they may suppress PSA production while continuing to spread, a process possibly involving lineage plasticity or neuroendocrine transformation.

The researchers recommend incorporating periodic imaging into patient monitoring, particularly during the initial two years of treatment with potent androgen receptor inhibitors like enzalutamide. This change could enhance early detection of clinically meaningful disease progression, potentially altering patient management strategies.

"This is a practice-changing paper suggesting that waiting for PSA to increase could delay detection of clinically meaningful disease growth and worse outcomes for patients," Dr. Sternberg emphasized.

Future clinical guidelines could benefit from these findings, suggesting a reevaluation of PSA monitoring and more defined imaging protocols to improve patient outcomes in advanced prostate cancer.